ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19, rhinovirus and influenza in populations at-risk of complications.
The company is based in Sydney and Melbourne, Australia and it has secured a Series A investment from the Brandon Capital Partners' managed funds, the Minderoo Foundation and Uniseed.
The company is based in Sydney and Melbourne, Australia and it has secured a Series A investment from the Brandon Capital Partners' managed funds, the Minderoo Foundation and Uniseed.
Location: Australia
Total raised: $51.4M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Brandon Ca... | brandoncap... |
| - | Stoic VC | stoicvc.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 22.10.2025 | Series B | $22.4M | Brandon Ca... |
| 11.02.2025 | - | $5M | - |
| 22.06.2021 | - | $24M | - |
Mentions in press and media 22
| Date | Title | Description |
| 22.10.2025 | ENA Respiratory Raises US$22.4M in Series B Financing | ENA Respiratory, a Melbourne, Australia-based clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, raised US$22.4m (AUD$34m) in Series B financ... |
| 07.05.2025 | ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer | Melbourne, Australia, 6 May 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny Simm... |
| 11.02.2025 | ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051 | Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a U... |
| 10.02.2025 | ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051 | MELBOURNE, Australia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it h... |
| 30.04.2024 | ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator | Melbourne, Australia, 29 April 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, anno... |
| 11.09.2023 | New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance | Melbourne, Australia and Milan, Italy, 11 September 2023 – ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunom... |
| 14.02.2023 | Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study | ENA Respiratory, a clinical-stage pharmaceutical company, announced that INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of respiratory viral infections, was found to significantly impac... |
| 12.05.2022 | ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected... |
| 11.05.2022 | ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray | SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk popu... |
| 16.03.2022 | First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray | ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of ... |
Show more